🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thanks to everyone who’s cheering on Houston Dynamo FC with us for Kick Cancer Night this evening. What a special night celebrating cancer survivors and their loved ones. #EndCancer

Great to meet with our lung cancer experts at MD Anderson Cancer Center and thanks for the consult! Eric K. Singhi, MD Natalie Vokes #ASCO2025

PFS benefit with anlotinib+doxo and anlotinib maintenance. Lower than expected ORR in doxo arm and almost impossible to believe equivalence in toxicity between the arms. Same question as doxo+trabectedin: what if sequential single agent were used? #ASCO25

Exciting initial activity of TDXd in DSRCT. #ASCO25

KS is still one of the most common cancers in the world. Phenomenal activity with abemaciclib. #ASCO25

Encouraging activity of abemaciclib in KS pts, with 84% response rate and no significant impact in CD4+ T-cell counts. Great to see how CDK4/6i are entering the sarcoma field, and good to have long-term safety/management data generated by our breast cancer med onc colleagues.

Spatial transcriptomics revealed two new subtypes of leiomyosarcoma that are potential prognostic biomarkers for this rare and aggressive type of soft tissue sarcoma. Our fellow, Dr. Ryan Denu, MD, PhD presented results at an #ASCO25 session moderated by our Dr. Elise Nassif Haddad. Read more:

1. Ryan Denu, MD, PhD "indentified 2 distinct subtypes: a dedifferentiated subtype with mesenchymal features (MES) and a differentiated subtype with enrichment of smooth muscle cell markers (SMC)." #leiomyosarcoma #sarcoma #ASCO25

Today on National Cancer Survivor Day we honor all sarcoma survivors; anyone who’s been diagnosed with cancer regardless of whether they are in treatment or completed treatment. We were fortunate to celebrate a full circle moment today with sarcoma survivor and SFA staff,

Is there a difference in outcomes for patients receiving morning or evening chemoimmunotherapy infusion ? #ASCO25 we have the first randomized trial and its positive! Several retrospective studies showed that morning immunotherapy infusions are associated with longer survival.

NEW content online! Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy bit.ly/44ZSbTd

Congrats Inimfon Jackson on a great presentation on disparities in chemotherapy delivery for breast cancer. Making us proud. #ASCO25 #endcancer MD Anderson Cancer Center

So proud of co-fellow Marija Sullivan, MD on a great presentation on real world implementation of Oncotype results. MD Anderson Cancer Center #ASCO25 #endcancer

Always a pleasure & fun to bump into Dr. Islam Sadek at ASCO Truly amazing person, putting all efforts to improve outcomes in #leukemia & enhance collaborations between HCPs, patients, institutions,... #ASCO25 #CML

Lifting weights reverses muscle aging.

Wagner #sarcoma uniform for the day #ASCO25

🙌Congrats to my terrific friend Cindy Y. Jiang (soon-to-be faculty MD Anderson Cancer Center) for leading this🌟 study on 9p21-loss in mUC, driving worse survival & + lung mets, likely via ↑ TGFβ-EMT signaling. Ongoing preclinical data in CDKN2A-MTAP DKO mice from our amazing #JJGao's lab

Enjoying #ASCO25 so far! Congrats to Andrew Brohl on his oral presentation on neoadjuvant lenvatinib + pembrolizumab in MCC. Results highlight the potential for new combination therapies and biomarkers. We also filmed a chat about exciting sarcoma breakthroughs! #MoffittASCO25

#foodforthought 🍔🍕🍪🤔: the impact of infusion time of #ICIs is huge! ⏰ How many of our #immune checkpoint inhibitor clinical trials which #failed in the randomised setting may have done so ‘cos there was no stratification for this? #ASCO25 #CircadianRhythm Jordi Remon

⭐️🚨Delighted to share the FINAL report from the #ARROW study #TissueAgnostic cohort 👉🏼Efficacy & safety of pralsetinib in RET fusion-positive solid tumors. All patients with PANCREATIC CANCER responded - including 2 complete responses PanCAN Journal of Clinical Oncology #RET #TissueAgnostic